Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Apellis Pharmaceuticals, Inc. (APLS)
since 2017 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Apellis Pharmaceuticals, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1492422.
Total stock buying since 2017: $72,055,913.
Total stock sales since 2017: $125,480,225.
Total stock option exercises since 2017: $17,781,278.
Table 3. Detailed insider trading at Apellis Pharmaceuticals, Inc. (APLS)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-09-02 | Chopas James George (VP/Chief Accounting Officer) | Sale | 548 | 28.08 | 15,386 |
| 2025-08-28 | Francois Cedric (Chief Executive Officer) | Sale | 49,963 | 28.39 | 1,418,449 |
| 2025-08-27 | Francois Cedric (Chief Executive Officer) | Sale | 175,037 | 28.19 | 4,934,293 |
| 2025-08-18 | Watson David O. (General Counsel) | Sale | 5,000 | 27.80 | 139,000 |
| 2025-07-17 | Francois Cedric (Chief Executive Officer) | Sale | 19,725 | 20.21 | 398,740 |
| 2025-07-17 | Francois Cedric (Chief Executive Officer) | Option Ex | 8,997 | 4.31 | 38,777 |
| 2025-07-16 | Watson David O. (General Counsel) | Sale | 5,000 | 19.55 | 97,750 |
| 2025-07-15 | Francois Cedric (Chief Executive Officer) | Sale | 1,900 | 20.09 | 38,167 |
| 2025-07-15 | Francois Cedric (Chief Executive Officer) | Option Ex | 800 | 4.31 | 3,447 |
| 2025-07-14 | Francois Cedric (Chief Executive Officer) | Sale | 137,465 | 20.19 | 2,774,868 |
| 2025-07-14 | Francois Cedric (Chief Executive Officer) | Option Ex | 65,203 | 4.31 | 281,024 |
| 2025-06-16 | Watson David O. (General Counsel) | Sale | 5,000 | 18.77 | 93,850 |
| 2025-05-21 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 12,780 | 3.76 | 48,052 |
| 2025-03-17 | Chopas James George (VP/Chief Accounting Officer) | Sale | 183 | 24.82 | 4,542 |
| 2025-03-05 | Watson David O. (General Counsel) | Sale | 5,569 | 25.10 | 139,787 |
| 2025-02-11 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 363 | 28.54 | 10,359 |
| 2025-01-29 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 365 | 29.52 | 10,776 |
| 2025-01-29 | Eisele Jeffrey (Chief Development Officer) | Sale | 278 | 29.52 | 8,207 |
| 2025-01-29 | Nicholson Nur (Chief Technical Officer) | Sale | 825 | 29.52 | 24,357 |
| 2025-01-29 | Lewis Karen (Chief People Officer) | Sale | 364 | 29.52 | 10,746 |
| 2025-01-29 | Townsend Adam J. (Chief Commercial Officer) | Sale | 695 | 29.52 | 20,519 |
| 2025-01-29 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 546 | 29.52 | 16,120 |
| 2025-01-29 | Francois Cedric (Chief Executive Officer) | Sale | 2,824 | 29.52 | 83,375 |
| 2025-01-29 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 826 | 29.52 | 24,386 |
| 2025-01-29 | Watson David O. (General Counsel) | Sale | 695 | 29.52 | 20,519 |
| 2025-01-22 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 1,396 | 30.43 | 42,474 |
| 2025-01-22 | Chopas James George (VP/Chief Accounting Officer) | Sale | 1,096 | 30.43 | 33,346 |
| 2025-01-22 | Eisele Jeffrey (Chief Development Officer) | Sale | 1,291 | 30.43 | 39,279 |
| 2025-01-22 | Nicholson Nur (Chief Technical Officer) | Sale | 3,948 | 30.43 | 120,121 |
| 2025-01-22 | Lewis Karen (Chief People Officer) | Sale | 1,751 | 30.43 | 53,275 |
| 2025-01-22 | Townsend Adam J. (Chief Commercial Officer) | Sale | 3,323 | 30.43 | 101,105 |
| 2025-01-22 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 3,088 | 30.43 | 93,955 |
| 2025-01-22 | Francois Cedric (Chief Executive Officer) | Sale | 13,551 | 30.43 | 412,302 |
| 2025-01-22 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 3,948 | 30.43 | 120,121 |
| 2025-01-22 | Watson David O. (General Counsel) | Sale | 3,323 | 30.43 | 101,105 |
| 2025-01-17 | Baumal Caroline (Chief Medical Officer) | Sale | 1,853 | 29.96 | 55,512 |
| 2025-01-17 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 1,235 | 29.96 | 36,998 |
| 2025-01-17 | Chopas James George (VP/Chief Accounting Officer) | Sale | 715 | 29.96 | 21,419 |
| 2025-01-17 | Nicholson Nur (Chief Technical Officer) | Sale | 2,145 | 29.96 | 64,259 |
| 2025-01-17 | Lewis Karen (Chief People Officer) | Sale | 1,241 | 29.96 | 37,177 |
| 2025-01-17 | Townsend Adam J. (Chief Commercial Officer) | Sale | 2,201 | 29.96 | 65,937 |
| 2025-01-17 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 1,730 | 29.96 | 51,827 |
| 2025-01-17 | Francois Cedric (Chief Executive Officer) | Sale | 6,007 | 29.96 | 179,957 |
| 2025-01-17 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 750 | 29.96 | 22,468 |
| 2025-01-17 | Watson David O. (General Counsel) | Sale | 2,201 | 29.96 | 65,937 |
| 2025-01-13 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 1,599 | 28.70 | 45,894 |
| 2025-01-13 | Chopas James George (VP/Chief Accounting Officer) | Sale | 783 | 28.70 | 22,473 |
| 2025-01-13 | Eisele Jeffrey (Chief Development Officer) | Sale | 264 | 28.70 | 7,577 |
| 2025-01-13 | Nicholson Nur (Chief Technical Officer) | Sale | 2,632 | 28.70 | 75,543 |
| 2025-01-13 | Lewis Karen (Chief People Officer) | Sale | 1,599 | 28.70 | 45,894 |
| 2025-01-13 | Townsend Adam J. (Chief Commercial Officer) | Sale | 2,685 | 28.70 | 77,064 |
| 2025-01-13 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 2,170 | 28.70 | 62,283 |
| 2025-01-13 | Francois Cedric (Chief Executive Officer) | Sale | 6,247 | 28.70 | 179,301 |
| 2025-01-13 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 2,288 | 28.70 | 65,670 |
| 2025-01-13 | Watson David O. (General Counsel) | Sale | 4,965 | 28.70 | 142,505 |
| 2025-01-06 | Baumal Caroline (Chief Medical Officer) | Sale | 2,816 | 33.81 | 95,214 |
| 2024-12-11 | Watson David O. (General Counsel) | Sale | 5,000 | 34.23 | 171,175 |
| 2024-09-23 | Dunlop A. Sinclair (Director) | Option Ex | 4,600 | 13.19 | 60,674 |
| 2024-09-16 | Dunlop A. Sinclair | Sale | 37,000 | 36.44 | 1,348,280 |
| 2024-09-03 | Chopas James George (VP/Chief Accounting Officer) | Sale | 550 | 39.49 | 21,720 |
| 2024-08-12 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Option Ex | 5,201 | 13.85 | 72,033 |
| 2024-06-28 | Dunlop A. Sinclair (Director) | Option Ex | 900 | 13.19 | 11,871 |
| 2024-06-21 | Dunlop A. Sinclair | Sale | 37,000 | 39.42 | 1,458,725 |
| 2024-05-20 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 24,500 | 3.76 | 92,120 |
| 2024-05-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 78,907 | 43.01 | 3,393,632 |
| 2024-05-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 78,907 | 4.31 | 340,089 |
| 2024-04-12 | Dunlop A. Sinclair (Director) | Option Ex | 1,500 | 13.19 | 19,785 |
| 2024-04-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 69,107 | 54.52 | 3,767,437 |
| 2024-04-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 69,107 | 3.76 | 259,842 |
| 2024-04-01 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 4,000 | 58.66 | 234,640 |
| 2024-04-01 | Sullivan Timothy Eugene (Chief Financial Officer) | Option Ex | 4,000 | 10.03 | 40,120 |
| 2024-03-19 | Dunlop A. Sinclair | Sale | 18,681 | 57.18 | 1,068,160 |
| 2024-03-18 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 9,913 | 56.90 | 564,049 |
| 2024-03-15 | Chopas James George (VP/Chief Accounting Officer) | Sale | 184 | 56.46 | 10,388 |
| 2024-03-13 | Nicholson Nur (Chief Technical Officer) | Sale | 11,220 | 57.72 | 647,618 |
| 2024-03-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 69,107 | 62.64 | 4,328,724 |
| 2024-03-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 69,107 | 3.67 | 253,622 |
| 2024-03-06 | Watson David O. (General Counsel) | Option Ex | 3,762 | 13.85 | 52,103 |
| 2024-02-12 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 597 | 67.77 | 40,456 |
| 2024-02-12 | Townsend Adam J. (Chief Commercial Officer) | Sale | 1,148 | 67.77 | 77,796 |
| 2024-02-12 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 1,431 | 67.77 | 96,974 |
| 2024-02-12 | Francois Cedric (Chief Executive Officer) | Sale | 3,962 | 67.77 | 268,492 |
| 2024-02-12 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 1,148 | 67.77 | 77,796 |
| 2024-02-12 | Watson David O. (General Counsel) | Sale | 781 | 67.77 | 52,926 |
| 2024-01-30 | Eisele Jeffrey (Chief Development Officer) | Sale | 971 | 65.53 | 63,629 |
| 2024-01-30 | Lewis Karen (Chief People Officer) | Sale | 883 | 65.53 | 57,862 |
| 2024-01-29 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 367 | 64.14 | 23,538 |
| 2024-01-29 | Eisele Jeffrey (Chief Development Officer) | Sale | 279 | 64.14 | 17,894 |
| 2024-01-29 | Nicholson Nur (Chief Technical Officer) | Sale | 835 | 64.14 | 53,555 |
| 2024-01-29 | Lewis Karen (Chief People Officer) | Sale | 367 | 64.14 | 23,538 |
| 2024-01-29 | Townsend Adam J. (Chief Commercial Officer) | Sale | 906 | 64.14 | 58,109 |
| 2024-01-29 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 906 | 64.14 | 58,109 |
| 2024-01-29 | Francois Cedric (Chief Executive Officer) | Sale | 2,843 | 64.14 | 182,344 |
| 2024-01-29 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 874 | 64.14 | 56,056 |
| 2024-01-29 | Watson David O. (General Counsel) | Sale | 906 | 64.14 | 58,109 |
| 2024-01-23 | Eisele Jeffrey (Chief Development Officer) | Sale | 7,378 | 63.69 | 469,904 |
| 2024-01-23 | Lewis Karen (Chief People Officer) | Sale | 4,286 | 63.69 | 272,975 |
| 2024-01-22 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 1,384 | 65.00 | 89,954 |
| 2024-01-22 | Chopas James George (VP/Chief Accounting Officer) | Sale | 1,061 | 65.00 | 68,960 |
| 2024-01-22 | Eisele Jeffrey (Chief Development Officer) | Sale | 1,607 | 65.00 | 104,448 |
| 2024-01-22 | Nicholson Nur (Chief Technical Officer) | Sale | 2,593 | 65.00 | 168,534 |
| 2024-01-22 | Lewis Karen (Chief People Officer) | Sale | 1,738 | 65.00 | 112,963 |
| 2024-01-22 | Townsend Adam J. (Chief Commercial Officer) | Sale | 3,413 | 65.00 | 221,831 |
| 2024-01-22 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 3,551 | 65.00 | 230,800 |
| 2024-01-22 | Francois Cedric (Chief Executive Officer) | Sale | 13,431 | 65.00 | 872,961 |
| 2024-01-22 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 3,913 | 65.00 | 254,329 |
| 2024-01-22 | Watson David O. (General Counsel) | Sale | 4,184 | 65.00 | 271,943 |
| 2024-01-17 | Eisele Jeffrey (Chief Development Officer) | Sale | 5,207 | 65.58 | 341,475 |
| 2024-01-17 | Lewis Karen (Chief People Officer) | Sale | 3,276 | 65.58 | 214,840 |
| 2024-01-16 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 1,631 | 66.81 | 108,965 |
| 2024-01-16 | Eisele Jeffrey (Chief Development Officer) | Sale | 438 | 66.81 | 29,262 |
| 2024-01-16 | Nicholson Nur (Chief Technical Officer) | Sale | 1,857 | 66.81 | 124,064 |
| 2024-01-16 | Townsend Adam J. (Chief Commercial Officer) | Sale | 2,235 | 66.81 | 149,318 |
| 2024-01-16 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 2,235 | 66.81 | 149,318 |
| 2024-01-16 | Francois Cedric (Chief Executive Officer) | Sale | 7,851 | 66.81 | 524,517 |
| 2024-01-16 | Watson David O. (General Counsel) | Sale | 4,240 | 66.81 | 283,270 |
| 2024-01-04 | Baumal Caroline (Chief Medical Officer) | Sale | 2,751 | 60.05 | 165,205 |
| 2023-12-19 | Watson David O. (General Counsel) | Sale | 3,905 | 57.19 | 223,338 |
| 2023-12-19 | Watson David O. (General Counsel) | Option Ex | 7,905 | 13.85 | 109,484 |
| 2023-12-14 | Dunlop A. Sinclair (Director) | Option Ex | 6,274 | 13.19 | 82,754 |
| 2023-12-01 | Townsend Adam J. (Chief Commercial Officer) | Sale | 110,000 | 60.90 | 6,699,440 |
| 2023-12-01 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 110,000 | 15.09 | 1,659,900 |
| 2023-12-01 | Dunlop A. Sinclair | Sale | 24,000 | 61.13 | 1,467,240 |
| 2023-12-01 | Scheibler Lukas (Chief Research Officer) | Sale | 10,000 | 60.00 | 600,000 |
| 2023-12-01 | Scheibler Lukas (Chief Research Officer) | Option Ex | 10,000 | 13.85 | 138,500 |
| 2023-11-30 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 14,158 | 54.76 | 775,263 |
| 2023-11-30 | Sullivan Timothy Eugene (Chief Financial Officer) | Option Ex | 14,158 | 10.03 | 142,004 |
| 2023-11-21 | Francois Cedric (Chief Executive Officer) | Sale | 5,000 | 48.80 | 244,000 |
| 2023-11-17 | Dunlop A. Sinclair (Director) | Sale | 8,894 | 49.99 | 444,619 |
| 2023-11-17 | Machiels Alec (Director) | Sale | 1,250 | 47.74 | 59,675 |
| 2023-11-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-11-14 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 45,000 | 3.76 | 169,200 |
| 2023-11-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 47.27 | 567,240 |
| 2023-11-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 17,494 | 2.67 | 46,708 |
| 2023-10-23 | Delong Mark Jeffrey (Chief Business & Strat Officer) | Sale | 131 | 46.04 | 6,030 |
| 2023-10-23 | Chopas James George (VP/Chief Accounting Officer) | Sale | 132 | 46.04 | 6,076 |
| 2023-10-17 | Dunlop A. Sinclair (Director) | Sale | 24,000 | 49.00 | 1,176,000 |
| 2023-10-17 | Machiels Alec (Director) | Sale | 1,250 | 48.50 | 60,625 |
| 2023-10-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-10-09 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 40.38 | 484,560 |
| 2023-10-09 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-09-18 | Nicholson Nur (Chief Technical Officer) | Sale | 20,350 | 44.18 | 899,022 |
| 2023-09-18 | Nicholson Nur (Chief Technical Officer) | Option Ex | 9,719 | 29.76 | 289,237 |
| 2023-09-18 | Machiels Alec (Director) | Sale | 1,250 | 45.00 | 56,250 |
| 2023-09-18 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-09-15 | Machiels Alec (Director) | Sale | 1,250 | 45.34 | 56,675 |
| 2023-09-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-09-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 42.87 | 514,439 |
| 2023-09-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-09-06 | Scheibler Lukas (Chief Research Officer) | Sale | 1,756 | 43.01 | 75,525 |
Insider trading activities including stock purchases, stock sales, and option exercises
of APLS listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Apellis Pharmaceuticals, Inc. (symbol APLS,
CIK number 1492422) see
the Securities and Exchange Commission (SEC) website.